COVID-19-associated multisystem inflammatory syndrome
|
COVID-19 Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
COVID-19-associated multisystem inflammatory syndrome On the Web |
|
American Roentgen Ray Society Images of COVID-19-associated multisystem inflammatory syndrome |
|
FDA on COVID-19-associated multisystem inflammatory syndrome |
|
CDC on COVID-19-associated multisystem inflammatory syndrome |
|
COVID-19-associated multisystem inflammatory syndrome in the news |
|
Blogs on COVID-19-associated multisystem inflammatory syndrome |
|
Risk calculators and risk factors for COVID-19-associated multisystem inflammatory syndrome |
For COVID-19 frequently asked inpatient questions, click here
For COVID-19 frequently asked outpatient questions, click here
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Harmeet Kharoud M.D.[2]
Synonyms and keywords: Multisystem Inflammatory Syndrome in Children (MIS-C)
Overview
Multisystem Inflammatory Syndrome in Children (MIS-C) is a condition that causes inflammation of some parts of the body like heart, blood vessels, kidneys, digestive system, brain, skin, or eyes. According to recent evidence, it is suggested that children with MIS-C had antibodies against COVID-19 suggesting children had COVID-19 infection in the past. This syndrome appears to be similar in presentation to Kawasaki disease, hence also called Kawasaki -like a disease. It also shares features with staphylococcal and streptococcal toxic shock syndromes, bacterial sepsis, and macrophage activation syndromes.[1]
Historical Perspective
Classification of Disease Severity of MIS-C
- Mild Disease
- Children with MIS-C fall under this category who-
- require minimal to no respiratory support.
- minimal to no organ injury
- normotensive
- Do not meet the criteria for ICU admission.
- Severe Disease
- Children with MIS-C fall under this category who-
- have significant oxygen requirements (HFNC, BiPAP, mechanical ventilation).
- have a mild-severe organ injury and ventricular dysfunction.
- have a vasoactive requirement.
- meet the criteria for ICU admissions
Pathophysiology
Differentiating Any Disease from other disease
Epidemiology and Demographics
- According to a recent study among the 186 children with MIS-C, the rate of hospitalization was 12% between March 16 and April 15 and 88% between April 16 and May 20.
- 80% of the children were admitted to the intensive care unit and 20% of the children required mechanical ventilation.
- 4% of the children required extracorporeal membrane oxygenation.
- The mortality rate among 186 children with MIS-C was 2%.
Age
- Among the 186 children with MIS-C distribution of age group was
- <1yr-7%
- 1-4yr-28%
- 5-9yr-25%
- 10-14yr-24%
- 15-20yr-16%.
Gender
- Among the 186 children with MIS-C
Comorbidities
- Children with MIS-C had following underlying comorbidities.
- Clinically diagnosed Obesity-8%
- BMI-Based Obesity-29%
- Cardiovascular diasease-3%
- Respiratory disease-18%
- Autoimmune disease or immunocompromising condition-5%
Organ System Involved
- 71% of children had involvement of at least four organ systems.
The most common organ system involved in MIS-C children among a total of 183 children were.
- Gastrointestinal(92%)
- Cardiovascular(80%)
- Hematologic(76%)
- Mucocutaneous(74%)
- Pulmonary(70%)
- Historical perspective
Risk Factors
Natural History, Complications and Prognosis
Natural history
Complications
- Severe myocardial infarction
- Cardiac failure/arrest
- ARDS
- Hypervolemia
- Acute Kidney Injury
- Peritonitis
- Thrombotic complications.
Prognosis
Diagnosis
Diagnostic Criteria
Preliminary WHO case definition: Children and adolescents
- 0–19 years of age with fever >3 days
AND
- Two of the following:
- Rash or bilateral non-purulent conjunctivitis or mucocutaneous inflammation signs (oral, hands or feet)
- Hypotension or shock
- Features of myocardial dysfunction, pericarditis, valvulitis, or coronary abnormalities (including ECHO findings or elevated Troponin/NT-proBNP)
- Evidence of coagulopathy (by PT, PTT, elevated D-Dimers)
- Acute gastrointestinal problems (diarrhea, vomiting, or abdominal pain)
AND
- Elevated markers of inflammation such as ESR, C-reactive protein, or procalcitonin
AND
- No other obvious microbial cause of inflammation, including bacterial sepsis, staphylococcal or streptococcal shock syndromes
AND
- Evidence of COVID-19 (RT-PCR, antigen test or serology-positive), or likely contact with patients with COVID-19
CDC Case Definition for MIS-C
- An individual aged <21 years presenting with fever, laboratory evidence of inflammation**, and evidence of clinically severe illness requiring hospitalization, with multisystem (>2) organ involvement (cardiac, renal, respiratory, hematologic, gastrointestinal, dermatologic or neurological);
AND
No alternative plausible diagnoses;
AND
Positive for current or recent SARS-CoV-2 infection by RT-PCR, serology, or antigen test; or exposure to a suspected or confirmed COVID-19 case within the 4 weeks prior to the onset of symptoms.
Signs and Symptoms
- Fever lasting 24 hours or longer.ref name=":2">"Guidance: Paediatric multisystem inflammatory syndrome temporally associated with COVID-19" (PDF). line feed character in
|title=at position 46 (help)</ref> - Vomiting
- Diarrhea
- Abdominal pain
- Skin rash
- Conjuctivitis
- High ESR
- Redness or swelling of the lips and tongue
- Lethargy
- Redness or swelling of the hands or feet
- Confusion
- Headache
- Sore throat
- Syncope
- Lymphadenopathy
Emergency Warning Signs
Physical Examination
Laboratory Findings
Blood Investigations
- Lymphopenia, Neutrophilia, Anemia, Thrombocytopenia have been seen in MIS-C pateints. Abnormal fibrinogen, Hypoalbuminaemia, elevated creatiine kinase (CK), LDH, triglycerides have been observed in MIS-C patients.
Inflammatory biomarkers
Elevation of inflammatory markers including ESR, C reactive protein and procalcitonin are usually seen in MIS-C. Increased level of Interleukin-6 (IL-6), Interleukin-10(IL-10) d-dimer, serum ferritin, prothrombin time have also been seen in MIS-C.
Cardiac biomarkers
Elevation of cardic enzymes including cardiac troponins (cardiac troponin I(cTnI) and cardiac troponin T (cTnT)) and Brain natriuretic peptide (BNP)) has been observed in MIS-C patients.
Radiological Findings
- Following Radiological Findings are observed in MIS-C patients.
| Test | Findings |
|---|---|
| Chest Xray | patchy symmetrical infiltrates, pleural effusion |
| Echocardiogram and EKG | myocarditis, valvulitis, pericardial effusion, coronary artery dilatation |
| Abdominal USG | colitis, ileitis, lymphadenopathy, ascites, hepatosplenomegaly |
Blood Culture, Viral PCR
- Absence of other potential causative organisms. IgGlevels and IgM levels of SARS-CoV-2 are detected.
Treatment
Medical Therapy
- All the children with MIS-C are treated as suspected COVID-19.
- Mild to Moderate cases of MIS-C are managed supportively.
- Supplemental oxygen is required in children with low oxygen saturation.
- Fluid resuscitation in 10 ml/kg aliquots with reevaluation after each bolus. Maintain euvolemia. Avoid hypervolemia.
- Anti-inflammatory treatments with Intravenous immunoglobulin(IVIG) with or without corticosteroids have shown a good response rate.
- Aspirin has been used primarily for its antiplatelet effect. It is recommended in all patients with MIS-C.[2]
- Anakinra is considered if fevers last more than 24 hours post steroids/IVIG or in the moderate or severe presentation.
- Tocilizumab is also considered if fevers last more than 24 hours post steroids/IVIG or in the moderate or severe presentation.
- Empiric antibiotics like vancomycin, ceftriaxone, and clindamycin are given for community-acquired shock presentation until cultures are negative for 48 hours.
| Presentation | Treatment |
|---|---|
| Mild Disease |
|
| Severe Disease |
|
Prevention of MIS-C
- MIS-C can be prevented by reducing the risk of child exposure to COVID-19 infection.